Rickenbach Josef H Von has bought stock on 2 days since Sep 2019

Josef H. von Rickenbach is a corporate insider and independent director at Aileron Therapeutics Inc. (ALRN), where he has served on the board since his appointment in 2019 and is reported as a Director and significant shareholder in recent SEC filings.( He is a veteran executive in the biopharmaceutical services and drug development industry, best known as co‑founder, Chairman, and Chief Executive Officer of PAREXEL International Corporation, which he led for roughly 35 years from its early 1980s beginnings as one of the first clinical research organizations through its IPO, global expansion to about 19,000 employees in more than 50 countries, and over 40 mergers and acquisitions before the company was taken private in 2017.(

Following his retirement from PAREXEL, von Rickenbach became Managing Director of stet vision LLC and co‑founded and led Helio Vision, Inc., an ophthalmic biopharma company that merged into Aldeyra Therapeutics in 2019.( He currently holds multiple board and advisory roles, including Chairman of the Board at ZAGENO Inc. and Rein Therapeutics, Senior Advisor to growth‑equity firm General Atlantic, and director or trustee positions at Javara, McLean Hospital, and the Network for Excellence in Health Innovation.( Earlier in his career he held roles at Schering‑Plough, 3M (East), and ERCO/ENSECO, building broad experience across the biopharma value chain.( Von Rickenbach earned a B.A. in Business Economics from Lucerne University in Switzerland and an M.B.A. from Harvard Business School, credentials that underpin his long record of leadership awards and recognition in the life sciences and business community.(

Written by Perplexity from public sources.